Agenerase Oral Solution
- Generic Name: amprenavir oral solution
- Brand Name: Agenerase Oral Solution
Agenerase Oral Solution (Amprenavir Oral Solution) side effects drug center
- Related Drugs
- Health Resources
- nausea
- vomiting
- diarrhea
- loose stools
- stomach pain
- numbness
- tingling (especially around your mouth)
- headache
- mood changes or depression
- rash
- fatigue
- changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist)
Agenerase (amprenavir) Oral Solution is a type of antiviral medication called a protease inhibitor, used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). It is not a cure for HIV or AIDS. The brand name Agenerase Oral Solution is discontinued, but generic versions may be available. Common side effects of Agenerase (amprenavir) Oral Solution include:
The recommended dose of Agenerase Oral Solution is based on body weight and age. Agenerase may interact with ritonavir, fluticasone, bepridil, St. John's wort, vitamin E, antibiotics, blood thinners, antidepressants, calcium channel blockers, cholesterol-lowering medicines, drugs that weaken the immune system, heart rhythm medications, other HIV /AIDS medicines, insulin or oral diabetes medications, medicines to treat erectile dysfunction, or seizure medications. Tell your doctor all medications and supplements you use. Agenerase may harm a fetus. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Take all of your HIV medicines as directed to control your infection while you are pregnant. Taking Agenerase together with birth control pills can make Agenerase less effective. Ask your doctor about using a non-hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while taking this drug. Breast milk transmits HIV; do not breastfeed.
Our Agenerase (amprenavir) Oral Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Agenerase Oral Solution Professional Information
SIDE EFFECTS
In clinical studies, adverse events leading to amprenavir discontinuation occurred primarily during the first 12 weeks of therapy, and were mostly due to gastrointestinal events (nausea, vomiting, diarrhea, and abdominal pain/discomfort), which were mild to moderate in severity.
Skin rash occurred in 22% of patients treated with amprenavir in studies PROAB3001 and PROAB3006. Rashes were usually maculopapular and of mild or moderate intensity, some with pruritus. Rashes had a median onset of 11 days after amprenavir initiation and a median duration of 10 days. Skin rashes led to amprenavir discontinuation in approximately 3% of patients. In some patients with mild or moderate rash, amprenavir dosing was often continued without interruption; if interrupted, reintroduction of amprenavir generally did not result in rash recurrence.
Severe or life-threatening rash (Grade 3 or 4), including cases of Stevens -Johnson syndrome, occurred in approximately 1% of recipients of AGENERASE (see WARNINGS). Amprenavir therapy should be discontinued for severe or life-threatening rashes and for moderate rashes accompanied by systemic symptoms.
Table 9. Selected Clinical Adverse Events of All Grades Reported
in > 5% of Adult Patients
| Adverse Event | PROAB 3001 Therapy-Naive Patients | PROAB 3006 NRTI-Experienced Patients | ||
| AGENERASE*/ Lamivudine/Zidovudine (n = 113) |
Lamivudine/ Zidovudine (n = 109) |
AGENERASE*/ NRTI (n = 245) |
Indinavir/ NRTI (n = 241) |
|
| Digestive | ||||
| Nausea | 74% | 50% | 43% | 35% |
| Vomiting | 34% | 17% | 24% | 20% |
| Diarrhea or loose stools | 39% | 35% | 60% | 41% |
| Taste disorders | 10% | 6% | 2% | 8% |
| Skin | ||||
| Rash | 27% | 6% | 20% | 15% |
| Nervous | ||||
| Paresthesia, oral/perioral | 26% | 6% | 31% | 2% |
| Paresthesia, peripheral | 10% | 4% | 14% | 10% |
| Psychiatric | ||||
| Depressive or mood disorders | 16% | 4% | 9% | 13% |
Among amprenavir-treated patients in Phase 3 studies, 2 patients developed de novo diabetes mellitus, 1 patient developed a dorsocervical fat enlargement (buffalo hump), and 9 patients developed fat redistribution.
In studies PROAB3001 and PROAB3006, no increased frequency of Grade 3 or 4 AST, ALT, amylase, or bilirubin elevations was seen compared to controls.
Pediatric Patients: An adverse event profile similar to that seen in adults was seen in pediatric patients.
Concomitant Therapy With Ritonavir: Tables 10 and 11 present adverse clinical events and laboratory abnormalities observed in subjects who received AGENERASE plus ritonavir. Since the trials were small, open- label, of varying duration, and often included different patient populations, direct comparisons to the frequency of events with AGENERASE Capsules alone (see Table 9) cannot be made.
Table 10. Selected Clinical Adverse Events of All Grades
Reported in Adult Patients in Open-Label Clinical Trials of AGENERASE Capsules
in Combination With Ritonavir Capsules
| Adverse Event | AGENERASE 1,200 mg plus Ritonavir 200 mg q.d.* (n = 101) |
AGENERASE 600 mg plus Ritonavir 100 mg b.i.d.† (n = 239) |
| Nausea | 31% | 23% |
| Diarrhea/loose stools | 30% | 28% |
| Headache | 16% | 12% |
| Abdominal symptoms | 14% | 14% |
| Vomiting | 11% | 9% |
| Rash | 10% | 9% |
| Paresthesias | 9% | 11% |
| Fatigue | 7% | 14% |
| Depressive & mood disorders | 4% | 9% |
| *Data from 2 open- label studies
in treatment- naive patients also receiving abacavir/lamivudine. †Data from 3 open- label studies in treatment- naive and treatment-experienced patients receiving combination antiretroviral therapy. |
||
Table 11. Grade 3/4 Laboratory Abnormalities Reported in ≥ 2% of Adult
Patients in Open-Label Clinical Trials of AGENERASE Capsules in Combination
With Ritonavir
| Laboratory Abnormality (non- fasting specimens) |
AGENERASE 1,200 mg plus Ritonavir 200 mg q.d.* (n = 101) |
AGENERASE 600 mg plus Ritonavir 100 mg b.i.d.† (n = 239) |
| Hypertriglyceridemia ( > 750 mg/dL) | 8% | 13% |
| Hyperglycemia ( > 251 mg/dL) | 2% | 3% |
| AST ( > 5 x ULN) | 3% | 5% |
| ALT ( > 5 x ULN) | 4% | 4% |
| Amylase ( > 2 x ULN) | 4% | 3% |
| *Data from 2 open- label studies
in treatment- naive patients also receiving abacavir/lamivudine. †Data from 3 open- label studies in treatment- naive and treatment-experienced patients receiving combination antiretroviral therapy. |
||
Read the entire FDA prescribing information for Agenerase Oral Solution (Amprenavir Oral Solution)